461 related articles for article (PubMed ID: 25297900)
1. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
[TBL] [Abstract][Full Text] [Related]
2. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
[TBL] [Abstract][Full Text] [Related]
3. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
4. IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.
Fastner G; Reitsamer R; Ziegler I; Zehentmayr F; Fussl C; Kopp P; Peintinger F; Greil R; Fischer T; Deutschmann H; Sedlmayer F
Int J Cancer; 2015 Mar; 136(5):1193-201. PubMed ID: 24995409
[TBL] [Abstract][Full Text] [Related]
5. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
6. The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.
Ustaalioglu BO; Bilici A; Kefeli U; Şeker M; Oncel M; Gezen C; Gumus M; Demirelli F
Am J Clin Oncol; 2012 Dec; 35(6):580-6. PubMed ID: 21926901
[TBL] [Abstract][Full Text] [Related]
7. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
[TBL] [Abstract][Full Text] [Related]
8. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy.
Miller M; Ottesen RA; Niland JC; Kruper L; Chen SL; Vito C
Ann Surg Oncol; 2014 Oct; 21(10):3317-23. PubMed ID: 25059788
[TBL] [Abstract][Full Text] [Related]
9. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE
Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.
Fitzal F; Mittlboeck M; Steger G; Bartsch R; Rudas M; Dubsky P; Riedl O; Jakesz R; Gnant M
Ann Surg Oncol; 2012 Feb; 19(2):519-26. PubMed ID: 21743980
[TBL] [Abstract][Full Text] [Related]
12. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results: double lumpectomies for multicentric breast carcinoma.
Kapoor NS; Chung A; Huynh K; Giuliano AE
Am Surg; 2012 Dec; 78(12):1345-8. PubMed ID: 23265123
[TBL] [Abstract][Full Text] [Related]
14. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?
Aurilio G; Bagnardi V; Graffeo R; Nolè F; Petit JY; Locatelli M; Martella S; Iera M; Rey P; Curigliano G; Rotmensz N; Munzone E; Goldhirsch A
Anticancer Res; 2014 Nov; 34(11):6677-83. PubMed ID: 25368274
[TBL] [Abstract][Full Text] [Related]
15. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up.
Chang JS; Park W; Kim YB; Lee IJ; Keum KC; Lee CG; Choi DH; Suh CO; Huh SJ
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):867-72. PubMed ID: 23747215
[TBL] [Abstract][Full Text] [Related]
17. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy.
Choi J; Laws A; Hu J; Barry W; Golshan M; King T
Ann Surg Oncol; 2018 Nov; 25(12):3541-3547. PubMed ID: 30128902
[TBL] [Abstract][Full Text] [Related]
18. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
19. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
